TMED9 as a Biomarker for Epithelial Ovarian Cancer (EOC)

November 2022 (Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea)

TMED9 (transmembrane emp24 domain-containing protein 9), which regulates the innate immune system and the protein transport via the ER-Golgi cargo pathway, has been implicated in various cancer types.

A new study from the Yonsei University College of Medicine, Seoul, Republic of Korea, aimed to elucidate the role and clinical significance of TMED9 in EOC (Cancer Genomics & Proteomics 19: 692-702, 2022).

👉 Our rabbit polyclonal antibody anti-TMED9 (HPA014650) was used on 417 tissue samples (212 EOCs, 52 borderline tumors, 83 benign tumors, and 70 non-adjacent normal ovarian epithelia).

TMED9 as a Biomarker for Epithelial Ovarian Cancer (EOC)
Representative IHC staining images of TMED9 in normal ovarian epithelial tissues, benign, borderline tumor, and epithelial ovarian cancer.

The results show:

✅ TMED9 mRNA and protein expression are upregulated in epithelial ovarian cancer compared to the normal ovarian epithelium.

✅ High expression of TMED9 is associated with advanced-stage epithelial ovarian cancer, particularly with the serous cell subtype of ovarian cancer.

✅ TMED9 knockdown reduces migration, invasion, cell proliferation, and colony formation of epithelial ovarian cancer cells.

Overall, the results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting TMED9 as a novel strategy for epithelial ovarian cancer treatment.

READ full article here.

Read here more about our antibodies in action.